[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565533":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":51,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":25,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Queen Mary Hospital, Hong Kong","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Timolol combination treatment","ACTIVE_COMPARATOR","Patients will received topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[13,14],"Drug: Timolol 0.5% eye drops and betamethasone valerate 0.1% cream","Drug: Betamethasone valerate 0.1% cream",{"label":16,"type":6,"description":17,"interventionNames":18},"Routine Arm","Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Timolol 0.5% eye drops and betamethasone valerate 0.1% cream","Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Betamethasone valerate 0.1% cream","The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[16,9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Wang Chun Kwok","CONTACT","+85222555336","kwokwch@hku.hk",[37],{"facility":38,"status":39,"city":40,"state":25,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Queen Mary Hospital","RECRUITING","Hong Kong","HK",{"type":43,"coordinates":44},"Point",[45,46],114.17469,22.27832,{"lat":46,"lon":45},[49],{"name":25,"role":33,"phone":50,"phoneExt":25,"email":25},"85222555336",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Kwok Wang Chun","Clinical Assistant Professor","100565533","phase-3-efficacy-and-safety-of-add-on-timolol-for-egfr-tki-and-alk-tki-induced-paronychia-100565533",false,"NCT06643416","Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","Efficacy and Safety of Add-on Topical Timolol in the Management of Epidermal Growth Factor and Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Inhibitor-induced Paronychia: a Prospective Randomized Open-labelled Trial","Inclusion criteria\n\n1. Aged 18 years or above, either males or females.\n2. Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.\n3. Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use\n4. Written informed consent obtained from patient\n5. Subjects are diagnosed with advanced non-small cell lung cancer\n\nExclusion criteria\n\n1. 1\\. Age below18\n2. 2\\. Patients who are allergic to, or contraindicated to topical timolol use\n3. 3\\. Pregnant women or nursing mother\n4. 4\\. Non-consenting patients\n5. 5\\. Subjects are not diagnosed with advanced non-small cell lung cancer","ALL","18 Years",{"count":65,"type":66},40,"ESTIMATED","INTERVENTIONAL",[69],"PHASE3","To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.",[72,73,74],"Paronychia","EGFR-TKI","ALK-TKI",[76,77,78,74],"EGFR TKI","paronychia","timolol","2024-10-16",{"date":81,"type":82},"2024-10-18","ACTUAL",{"date":84,"type":66},"2024-10-09",{"date":86,"type":66},"2025-12-31",{"name":5,"class":6},1]